Marin Nishimura

TitleResident Physician
InstitutionUniversity of California San Diego
Address200 W. Arbor Drive #8425
San Diego CA 92103
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Diego, San DiegoFellowship2021Cardiovascular Disease
    University of California, San Diego, San DiegoResidency2018Internal Medicine
    University of California, Davis, School of Medicine, SacramentoDoctor of Medicine2015Doctor of Medicine
    University of California, San Diego, San DiegoMaster of Science2010Biology
    University of California, San Diego, San DiegoBachelor of Science2008Biochemistry and Cell Biology

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Nishimura M, Maisel AS. Biomarkers: a window into the pathophysiology of atrial fibrillation in heart failure with reduced vs. preserved ejection fraction. Eur Heart J. 2018 Nov 14; 39(43):3876-3878. PMID: 30428036.
      View in: PubMed
    2. Giancaterino S, Lupercio F, Nishimura M, Hsu JC. Current and Future Use of Insertable Cardiac Monitors. JACC Clin Electrophysiol. 2018 Nov; 4(11):1383-1396. PMID: 30466842.
      View in: PubMed
    3. Nishimura M, Brann A, Chang KW, Maisel AS. The Confounding Effects of Non-cardiac Pathologies on the Interpretation of Cardiac Biomarkers. Curr Heart Fail Rep. 2018 Jul 10. PMID: 29987498.
      View in: PubMed
    4. Nishimura M, Sab S, Reeves RR, Hsu JC. Percutaneous left atrial appendage occlusion in atrial fibrillation patients with a contraindication to oral anticoagulation: a focused review. Europace. 2017 Dec 08. PMID: 29228158.
      View in: PubMed
    5. Nishimura M, Thomas I, Hsu JC. Benefits of Contemporary Implantable Cardioverter Defibrillators in Patients With Improved Ejection Fraction: When Is the Most Clinically Relevant Time to Evaluate? JAMA Cardiol. 2017 Dec 01; 2(12):1397. PMID: 28973138.
      View in: PubMed
    6. Nishimura M, Hsu JC. Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and End-Stage Renal Disease. Am J Cardiol. 2018 Jan 01; 121(1):131-140. PMID: 29132650.
      View in: PubMed
    7. Nishimura M, Sab S, Birgersdotter-Green U, Krummen D, Schricker A, Raissi F, Hoffmayer KS, Feld GK, Hsu JC. Reasons for and predictors of acute hospitalization versus elective outpatient implantable cardioverter-defibrillator implantation and subsequent differential clinical outcomes. J Interv Card Electrophysiol. 2017 Oct; 50(1):85-93. PMID: 28844089.
      View in: PubMed
    8. Nishimura M, Hsu JC. A Cautionary Tone Before Expanded Adoption of the Proposed CHA2DS2-VASc R Score. J Am Coll Cardiol. 2017 Jan 17; 69(2):251. PMID: 28081839.
      View in: PubMed
    9. Arbit B, Nishimura M, Hsu JC. Reversal agents for direct oral anticoagulants: A focused review. Int J Cardiol. 2016 Nov 15; 223:244-250. PMID: 27541665.
      View in: PubMed
    10. Singh GD, Nishimura M, Rogers JH, Amsterdam EA. Pain at the game: spontaneous coronary artery dissection. Am J Med. 2014 Dec; 127(12):1160-3. PMID: 25132346.
      View in: PubMed
    11. Godoy J, Nishimura M, Webster NJ. Gonadotropin-releasing hormone induces miR-132 and miR-212 to regulate cellular morphology and migration in immortalized LbetaT2 pituitary gonadotrope cells. Mol Endocrinol. 2011 May; 25(5):810-20. PMID: 21372146; PMCID: PMC3082323.